Organogenesis Holdings Inc
NASDAQ:ORGO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.28
4.49
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ORGO stock under the Base Case scenario is 3.294 USD. Compared to the current market price of 3.755 USD, Organogenesis Holdings Inc is Overvalued by 12%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Organogenesis Holdings Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ORGO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Organogenesis Holdings Inc
Balance Sheet Decomposition
Organogenesis Holdings Inc
Current Assets | 234.2m |
Cash & Short-Term Investments | 89.9m |
Receivables | 105.9m |
Other Current Assets | 38.3m |
Non-Current Assets | 209m |
PP&E | 126.5m |
Intangibles | 42.9m |
Other Non-Current Assets | 39.5m |
Current Liabilities | 85.7m |
Accounts Payable | 29.4m |
Accrued Liabilities | 39m |
Other Current Liabilities | 17.3m |
Non-Current Liabilities | 93.9m |
Long-Term Debt | 59m |
Other Non-Current Liabilities | 34.9m |
Earnings Waterfall
Organogenesis Holdings Inc
Revenue
|
448.4m
USD
|
Cost of Revenue
|
-111.5m
USD
|
Gross Profit
|
336.9m
USD
|
Operating Expenses
|
-324.9m
USD
|
Operating Income
|
12m
USD
|
Other Expenses
|
-28.5m
USD
|
Net Income
|
-16.5m
USD
|
Free Cash Flow Analysis
Organogenesis Holdings Inc
USD | |
Free Cash Flow | USD |
ORGO Profitability Score
Profitability Due Diligence
Organogenesis Holdings Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Organogenesis Holdings Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
ORGO Solvency Score
Solvency Due Diligence
Organogenesis Holdings Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Organogenesis Holdings Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ORGO Price Targets Summary
Organogenesis Holdings Inc
According to Wall Street analysts, the average 1-year price target for ORGO is 4.463 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.
Dividends
Current shareholder yield for ORGO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ORGO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
Contact
IPO
Employees
Officers
The intrinsic value of one ORGO stock under the Base Case scenario is 3.294 USD.
Compared to the current market price of 3.755 USD, Organogenesis Holdings Inc is Overvalued by 12%.